UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trialReuben Benjamin, Victoria Potter, Nitin Jain et al.|The Lancet Haematology|2022Cited by 139
Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?Alice Mason, Christopher J Edwards, Clive Holmes|Autoimmunity Reviews|2018Cited by 59
Lupus, vaccinations and COVID-19: What we know nowAlice Mason, Christopher J Edwards, Saul N. Faust et al.|Lupus|2021Cited by 29
Tyrosine kinase 2 inhibitors in autoimmune diseasesChethana Ramakrishna, Christopher J Edwards, Alice Mason|Autoimmunity Reviews|2024Cited by 19
Clinical management of Lupus patients during the COVID-19 pandemicAlice Mason, Christopher J Edwards, Emily Rose|Lupus|2020Cited by 18